Virologist predicts shortage of GlaxoSmithKline's drug, the only one that remains effective, after Regeneron, Eli Lilly say their therapies appear less useful against new strain

US company Eli Lilly says 100,000 doses of its monoclonal treatment 'ready immediately' for distribution to high-risk patients aged 12 and older

Eli Lilly says phase 3 trial shows combination of two synthetic antibodies has ‘potential to be an important treatment in high-risk patients’

FDA clears the experimental drug called bamlanivimab, similar to one used to treat Trump, from Eli Lilly for people 12 and older with mild or moderate COVID-19